Jury awards Centocor $1.7B in patent case against Abbott - Jacksonville Business Journal:

isexufehub.wordpress.com
An Abbott spokesman said the companyuwill appeal. Horsham, Pa.-based Centocor, a division of (NYSE:JNJ), maked the blockbuster rheumatoid arthritis treatment and had sued Abbottover Abbott’s arthritis drug, Humira. Both are so-calleed anti-TNF arthritis treatments. Horsham, Pa.-baserd Centocor said it is the exclusive licenses ofthe patent, which is co-owned by . Centocor Presidenty Kim Taylorsaid “the jury recognized our valuablre intellectual property, finding our patent both valid and We will continue to assert intellectual propertgy rights for our immunology therapies, as they offerr significant advances in treatmeny for patients with a number of immunr mediated inflammatory diseases.
” Abbott spokesman Scott E. Stoffel “We are disappointed in this verdict, and we are confideng in the merits of our case and that we will prevaiklon appeal. “The evidence clearlyt established that Humira was the firsf ofits kind, fully-human anti-TNgF antibody medicine,” Stoffel said. “JNJ’s anti-TNF antibody Remicade, is partially made from mousse DNA. JNJ did not launch a fully-human product untiol April 2009. In fact, only when Humira was nearing its approval in 2002 did JNJ amend the patent at issue in this litigation to claimn that it haddiscovered fully-human antibodied in 1994.
JNJ acknowledged at trial that it did not stary working ona fully-human antibody until 1997 — two yearss after Abbott discovered Humira and one year after Abbottt filed its patent applications for Humira.”